Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.39 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29730915 | 0.98 | PAOX (0.41) | PAOXCHRM2KDM4AHIF1ATET2 | |
| SCHEMBL12901296 | 0.95 | PAOX (0.39) | PAOXCHRM2KDM4AHIF1ATET2 | |
| Hydrochloric Acid SCHEMBL19924865 | 0.93 | PAOX (0.41) | PAOXCHRM2KDM4AHIF1ATET2 | |
| SCHEMBL6546705 | 0.89 | CA12 (0.47) | PAOXCHRM2MEN1ALDH1A1KMT2A | |
| SCHEMBL6901460 | 0.87 | PAOX (0.34) | PAOXCHRM2KDM4AHIF1ATET2 | |
| SCHEMBL8381768 | 0.87 | PAOX (0.43) | PAOXCHRM2KDM4AHIF1ATET2 | |
| SCHEMBL6898516 | 0.87 | PAOX (0.39) | PAOXCHRM2KDM4AHIF1ATET2 | |
| SCHEMBL13737325 | 0.86 | PAOX (0.41) | PAOXCHRM2KDM4AHIF1ATET2 | |
| SCHEMBL8386967 | 0.85 | PAOX (0.45) | PAOXCHRM2KDM4AHIF1ATET2 | |
| SCHEMBL5507927 | 0.84 | PAOX (0.55) | PAOXLMNAKDM4ESMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12213503-B2 | Method of treating plant and method of making plant-based food or drink product | NICHIA CORPORATION (JP) | 2025-02-04 | — | — | US | disclosed |
| US-20220039437-A1 | METHOD OF TREATING PLANT AND METHOD OF MAKING PLANT-BASED FOOD OR DRINK PRODUCT | NICHIA CORPORATION (JP) | 2022-02-10 | — | — | US | disclosed |
| US-20110045027-A1 | Adjuvant | GLAXO GROUP LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-1317424-A2 | POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | MediQuest Therapeutics, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| EP-1296931-A2 | POLYAMINE ANALOGUES AS CYTOTOXIC AGENTS | MediQuest Therapeutics, Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001092218-A2 | POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | ORIDIGM CORPORATION (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001072685-A2 | POLYAMINE ANALOGUES AS CYTOTOXIC AGENTS | ORIDIGM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
| EP-1001927-A2 | NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | ORIDIGM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999003823-A2 | NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | ORIDIGM CORPORATION (US) | 1999-01-28 | — | — | WO | disclosed |
| WO-1996040096-A1 | INHIBITION OF CANCER CELL GROWTH, PROLIFERATION AND METASTASIS USING N,N'-DIBENZYL-α,φ-DIAMINOALKANES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5498522-A | ANTITUMOR AGENTS OR ANTICARCINOGENIC AGENTS | HEALTH RESEARCH, INC. (US) | 1996-03-12 | — | — | US | disclosed |
| US-5456908-A | Inhibiting cellular uptake of polyamines by contacting cells with transport inhibitory amount of polymer or copolymer of said polyamines | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1995-10-10 | — | — | US | disclosed |
| EP-0297533-A2 | Novel acetylpolyamine amidohydrolase | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1989-01-04 | — | — | EP | disclosed |
| EP-0144951-B1 | N-2,3-BUTADIENYL-1,4-BUTANEDIAMINE DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045027-A1 | Adjuvant | TLR3, TLR9, TLR7 | PAOX 1262/4885CHRM2 3097/4885KDM4A 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.